SEC Form 4 · accession 0001562180-17-001719
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Cloonan
Officer — Chief Business Officer
Period of report
May 1, 2017
Accepted (ET)
May 4, 2017 · 11:36 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $73.43 | May 1, 2017 | A | 185,000 | A | — | May 1, 2027 | Common Stock | 185,000 | 185,000 | D |
Explanation of responses
- F1The securities awarded on 5/01/2017 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2016 Inducement Equity Plan. Options to purchase 46,250 shares of common stock shall vest on the one year anniversary starting from April 24, 2017 with 138,750 shares vesting in 36 equal monthly installments thereafter.